europe-nuclear-medicine-market-trends-and-forecasts-2014-2020-industry
Published

November 2016

Europe Nuclear Medicine Market - Trends and Forecasts (2016-2021)

Purchase Report
$3850
Single user license
$4000
Team license
$8250
Corporate license

The European nuclear medicine market is expected to reach USD 5.63 billion by the end of 2021, growing at a CAGR of around 10% from 2016 to 2021.

Nuclear medicine utilizes radioisotopes for application in diagnosis and treatment of diseases. The drugs containing radionuclides are said to be radiopharmaceuticals. Their uses in radiological imaging include Magnetic Resonance Imaging (MRI), Computerized tomography (CT), Positron Emission Tomography (PET) and Single Proton Emission Tomography (SPECT).

Europe Nuclear Medicine Market-Market Dynamics

The use of nuclear medicine for diagnostic purposes is gaining importance in Europe rapidly. There has been increased use of SPECT, PET, CT and MRI for diagnosis of cardiac diseases, brain diseases, cancer and many others. Nuclear medicine is being used for therapeutic purposes for treatment of Alzheimer’s disease, coronary heart diseases, bone metastasis, different medical conditions affecting the thyroid gland, scar -tissue removal and many cancers. In Europe, treatment for thyrotoxicosis through nuclear medicine has a large share in nuclear medicine therapeutics market. Advancements in diagnostic imaging are bringing in more use of nuclear medicine.

Drivers

The key driving factor for the market in Europe is the umbrella organization for nuclear medicine, the European Association for Nuclear Medicine (EANM) in Europe, which stands ready for political follow-up and professional input to guarantee patient care and safety throughout Europe. Other driving factors include:

  • Increasing incidence of cancer, thyroidal diseases, endocrinal diseases, and cardiac ailments
  • Rise in applications of SPECT and PET with advancement of technology
  • Growing awareness amongst physicians
  • Public awareness for better healthcare

Restraints

Some of the factors restraining the market growth are:

  • Short half-life of radiopharmaceuticals
  • High capital investment required for development
  • Stringent regulatory guidelines

Opportunities

The market offers ample opportunities to the players in the form of:

  • Increasing imaging technologies
  • Potential radioisotopes in the pipeline
  • Increasing neurological applications
  • Increasing cyclotron-based production

The European nuclear medicine market has been segmented based on type and application. The segmentation based on type of product has been further divided based on diagnostic market and therapeutic market, wherein, the diagnostics market has been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes that include Rubidium-82, Flourine-18, and the therapeutics category has been segmented into Alpha emitters (Radium-223), Beta Emitters(includes Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (includes iodine-125, Cesium-131, Palladium-103, & Iridium-192). The segmentation based on application has been similarly subdivided based on diagnostic and therapeutic application. The diagnostic application includes the application of SPECT and PET in Cardiology, Neurology, Oncology and others. The therapeutic applications include application in Oncology, Thyroid, Endocrinology and various other therapeutic areas.

On the basis of geography, the market has been segmented into the United Kingdom, Germany, France, Scandinavia, Italy, Spain, and the Benelux countries. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. France, UK, and Germany lead when it comes to the use of nuclear medicine. 

Currently, diagnostics segment holds the largest share in nuclear medicine market, in which SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share.

Some of the key players in the market are:            

  • Cardinal Health, Inc.
  • GE Healthcare
  • IBA Group
  • Lantheus Medical Imaging
  • Nordion, Inc.
  • NTP Radioisotopes
  • Siemens Healthcare
  • Triad Isotope

What the Report Offers

  • Market definition for the European nuclear medicine market along with identification of key drivers and restraints for the market.
  • Market analysis for the European nuclear medicine market, with region-specific assessments and competition analysis on a global and regional scale.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
  • Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
  • Identification and analysis of the macro and micro factors that affect the European nuclear medicine market on a regional scale.
  • A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
RELATED REPORTS

Confused about which report to get?

Download a full report to understand our capabilities
Purchase Report
$3850
Single user license
$4000
Team license
$8250
Corporate license
Our Clients Include View All

Looking to Customize Report?